Biomarin Pharmaceutical Inc. BMRN
Super Investor & Insider
2
Fondi che lo detengono
#410
Rank consenso
2.9%
% dei portafogli
$1.22B
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Dodge & Cox · Dodge & Cox | 0.45% | Reduce 0.07% | 14,561,759 | $822.6M |
| Viking Global Investors · Viking Global Investors | 1.12% | Add 16.98% | 7,062,077 | $398.9M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
BioMarin Pharmaceutical Inc. is a leading global biotechnology company specializing in the development and commercialization of therapies for people with serious and life-threatening rare genetic diseases. Its portfolio includes eight approved treatments targeting conditions such as mucopolysaccharidosis types I, IVA, …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees3,221
TickerBMRN
Statistics
Market Cap$10.57B
Revenue (TTM)$3.22B
Net Income$348.9M
Net Margin10.8%
EPS$1.80
P/E39.96
P/S3.31
P/B1.73
EV/EBITDA15.96
ROE4.5%
Dividend Yield—
Price$54.71
Data: Twelve Data · Revenue = mcap / P/S